SCHEMBL8150746

SCHEMBL8150746

O=C(O)c1ncc2ccccc2c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.50
MAOA P21397 1/20 0.50
EGLN1 Q9GZT9 5/20 0.47
ALDH1A1 P00352 2/20 0.44
MAPT P10636 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 2/20 0.42
GPR3 P46089 1/20 0.42
NR4A1 P22736 1/20 0.41
NR4A2 P43354 1/20 0.41
NR4A3 Q92570 1/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
GLA P06280 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
EGLN2 Q96KS0 5/20 0.40
DHODH Q02127 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2293486 0.84 MAOA (0.49) LDHAMAOAEGLN1KDM4EGPR3
SCHEMBL15631107 0.80 MAOA (0.49) LDHAMAOAEGLN1KDM4EGPR3
SCHEMBL28007224 0.80 MAOA (0.52) MAOAEGLN1ALDH1A1MAPTKDM4E
SCHEMBL27651389 0.79 LMNA (0.45) ALDH1A1MAPTSMN1; SMN2KDM4EGPR3
SCHEMBL821293 0.78 EGLN1 (0.68) EGLN1EGLN2
SCHEMBL31501044 0.78 EGLN1 (0.68) EGLN1EGLN2
SCHEMBL29726498 0.77 EGLN1 (0.70) EGLN1EGLN2
SCHEMBL21361727 0.77 EGLN1 (0.70) EGLN1EGLN2
SCHEMBL25106669 0.76 CTRC (0.42) EGLN1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL6718692 0.76 DHODH (0.42) EGLN1ALDH1A1SMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213569-A1 METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY NEW YORK UNIVERSITY (US) 2025-07-03 US disclosed
WO-2024155884-A1 HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2024-07-25 WO disclosed
CN-104470899-B The 4 isoquinolinol compounds as HIF hydroxylase inhibitors 菲布罗根有限公司 2017-12-26 CN disclosed
CN-1117079-C Substituted isoquinoline-3-formamides compounds, its preparing method and its use as medicine FIBRE GENE INC (US) 2003-08-06 CN disclosed
US-6093730-A AN ENZYME INHIBITORS OF PROLYL-4-HYDROXYLASE FOR TREATING FIBROTIC DISORDERS AND INHIBITING COLLAGEN BIOSYNTHESIS HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) 2000-07-25 US disclosed
CN-1218802-A Substituted isoquinoline-3-formamides compounds, its preparing method and its use as medicine HOECHST MARION ROUSSEL CO LTD (DE) 1999-06-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213569-A1 METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY DCLRE1B, RNASE1, ADAR LDHA 1650/4885MAOA 457/4885EGLN1 4200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.